Skip to Content
We are a clinical-stage biotechnology company pioneering
the development of lentivirus-based first-in-class gene and cell therapies in cancer.
At Genenta, we use gene-based cytokine delivery to activate  the immune system within the tumor,
providing a controlled, targeted and enduring anti-tumor response.

Financial Metrics

Stock Chart

Data Provided by Refinitiv. Minimum 15 minutes delayed.

To contact our Investor Relations team please complete the Investor Contact form under IR Resources or write IR@genenta.com

Stay Informed with Email Alerts

Sign Up